PPI fracture link
May 27, 2010
HIGH doses or long-term use of
proton pump inhibitors can lead to
a possible increased risk of
fractures, according to an alert
issued this week by the US Food
and Drug Administration.
The FDA said studies suggest a
possible increased risk of fractures
of the hip, wrist and spine with the
use of PPIs for one year or more.
“Because these products are used
by a great number of people, it’s
important for the public to be
aware of this possible increased
risk, and when prescribing proton
pump inhibitors health care
professionals should consider
whether a lower dose or shorter
duration of therapy would
adequately treat the patient’s
condition”.
Labelling of PPI products will be
changed in the USA to describe
the possible increased risk.
MEANWHILE the FDA has also
given approval for Lumizime
(alglucosidase alfa) for patients
aged 8 years and older with lateonset
(non-infantile) Pompe
disease, a rare genetic disorder
which causes heart and skeletal
muscle weakness, progressing to
death from respiratory failure.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 May 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 10
